logo
Plus   Neg
Share
Email

Swedish Shareholders' Association Recommends To Accept Vonovia' Offer For Hembla

Vonovia said that the Swedish Shareholders' Association recommended its members to accept Vonovia's offer for Hembla. The Association stated that shareholders who choose not to tender their shares should be prepared that the liquidity in the share will be low in the future even if the Hembla share remains listed.

The offer of 215 Swedish kronor per share represents a value premium of 16.6% compared to Hembla's EPRA NAV (long term net asset value) per share of about 184 Swedish kronor as of 30 September 2019.

Vonovia launched a mandatory offer to the shareholders in Hembla On 7 November 2019.

Vonovia said today that it is already a majority shareholder controlling about 72.3 %
of the voting rights in Hembla and intends to be a long-term owner. Vonovia intends to continue with Hembla's existing dividend policy of paying no dividend to its shareholders in the coming years.

Vonovia noted that the acceptance period for the offer ends on 9 December, 2019. It has made it clear that the price in the offer is full and final.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT